Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects

Kappelle, Paul J. W. H. ; Lambert, Gilles ; Dahlbäck, Björn LU ; Nielsen, Lars Bo and Dullaart, Robin P. F. (2011) In Atherosclerosis 214(2). p.492-494
Abstract
Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine models, and may be regulated by pathways involved in LDL metabolism. Proprotein convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor processing. We determined the extent to which plasma apoM is related to PCSK9 levels in subjects with varying degrees of obesity. Methods: We sought correlations between plasma apoM and PCSK9, measured using recently developed ELISAs, in 79 non-diabetic subjects. Results: ApoM and PCSK9 levels were both correlated positively with total cholesterol, non-HDL cholesterol, LDL cholesterol and apoB (P < 0.05 to P < 0.001). ApoM correlated positively with PCSK9 in lean individuals (n = 37, r = 0.337, P =... (More)
Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine models, and may be regulated by pathways involved in LDL metabolism. Proprotein convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor processing. We determined the extent to which plasma apoM is related to PCSK9 levels in subjects with varying degrees of obesity. Methods: We sought correlations between plasma apoM and PCSK9, measured using recently developed ELISAs, in 79 non-diabetic subjects. Results: ApoM and PCSK9 levels were both correlated positively with total cholesterol, non-HDL cholesterol, LDL cholesterol and apoB (P < 0.05 to P < 0.001). ApoM correlated positively with PCSK9 in lean individuals (n = 37, r = 0.337, P = 0.041), but not in overweight subjects (n = 32, r = 0.125, P = 0.50) and in obese subjects (n = 10, r = -0.055, P = 0.88). Conclusions: The PCSK9 pathway may contribute to plasma apoM regulation in humans. The influence of PCSK9 on circulating apoM appears to be modified by adiposity. (C) 2010 Elsevier Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Apolipoprotein M, Apolipoprotein B, LDL cholesterol, Obesity, PCSK9
in
Atherosclerosis
volume
214
issue
2
pages
492 - 494
publisher
Elsevier
external identifiers
  • wos:000286651100043
  • scopus:79151476997
  • pmid:21122852
ISSN
1879-1484
DOI
10.1016/j.atherosclerosis.2010.10.041
language
English
LU publication?
yes
id
92819ffc-6ef8-4c56-90a9-eb4d7d9e8cba (old id 1882687)
date added to LUP
2016-04-01 09:48:02
date last changed
2022-01-25 08:47:42
@article{92819ffc-6ef8-4c56-90a9-eb4d7d9e8cba,
  abstract     = {{Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine models, and may be regulated by pathways involved in LDL metabolism. Proprotein convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor processing. We determined the extent to which plasma apoM is related to PCSK9 levels in subjects with varying degrees of obesity. Methods: We sought correlations between plasma apoM and PCSK9, measured using recently developed ELISAs, in 79 non-diabetic subjects. Results: ApoM and PCSK9 levels were both correlated positively with total cholesterol, non-HDL cholesterol, LDL cholesterol and apoB (P &lt; 0.05 to P &lt; 0.001). ApoM correlated positively with PCSK9 in lean individuals (n = 37, r = 0.337, P = 0.041), but not in overweight subjects (n = 32, r = 0.125, P = 0.50) and in obese subjects (n = 10, r = -0.055, P = 0.88). Conclusions: The PCSK9 pathway may contribute to plasma apoM regulation in humans. The influence of PCSK9 on circulating apoM appears to be modified by adiposity. (C) 2010 Elsevier Ireland Ltd. All rights reserved.}},
  author       = {{Kappelle, Paul J. W. H. and Lambert, Gilles and Dahlbäck, Björn and Nielsen, Lars Bo and Dullaart, Robin P. F.}},
  issn         = {{1879-1484}},
  keywords     = {{Apolipoprotein M; Apolipoprotein B; LDL cholesterol; Obesity; PCSK9}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{492--494}},
  publisher    = {{Elsevier}},
  series       = {{Atherosclerosis}},
  title        = {{Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects}},
  url          = {{http://dx.doi.org/10.1016/j.atherosclerosis.2010.10.041}},
  doi          = {{10.1016/j.atherosclerosis.2010.10.041}},
  volume       = {{214}},
  year         = {{2011}},
}